Present era of drug safety in India: An overview
Keywords:
World Health Organization, CDSCO, pharmacovigilance, adverse drug reactionAbstract
Introduction: Common Adverse Drug Reactions (ADR), evaluated by drug clinical trial studies, whereas an individual or specific population might suffer reactions after prolonged dormancy. Pharmacovigilance (PV) is a scientific investigation dealing with and keeping regular vigil on the drugs being used.
Methods: The Indian Pharmacopoeia Commission (IPC) and other regulatory authorities like a National Coordination Committee (NCC) via the Central Drug Standard Control Organization (CDSCO) manage PV activity in synchronicity. Indian Pharmacovigilance (PV) system requires carving, therefore the Pharmacovigilance Program of India (PvPI) was enforced by the government in the year 2010, relying on exact ADR detection, evaluation, and reporting.
Results: Thus, several regional, zonal and peripheral centers are developed for ADR reporting. Clinicians, Nurses, laypersons, pharmacists, and other healthcare professionals can fill ADR reporting forms online or offline at the nearest centers in suitable languages. Additionally, a toll-free number and mobile app could be used for reporting ADR. Every reported ADR gets collected and processed at the centers through Vigi-flow software, which detects and assesses the signal strength reported at CDSCO and World Health Organisation (WHO) for the required regulatory action.
Conclusions: The final decision of CDSCO-WHO is passed by a suitable media source for the advancement of society's health.
References
Alam, M. S., Pillai, K. K., Abdi, S., Kapur, P., Pillai, P. K., & Nagarajan, K. (2018). Adverse drug reaction monitoring during antimicrobial therapy for septicemia patients at a university hospital in New Delhi. The Korean journal of internal medicine, 33(6), 1203–1209.
Amale, P. N., Deshpande, S. A., Nakhate, Y. D., Arsod, N. A. (2018). Pharmacovigilance process in India: An overview. Journal of pharmacovigilance, 6(2), 1-7.
Aranaz-Andrés, J. M., Aibar, C., Limón, R., Mira, J. J., Vitaller, J., Agra, Y., & Terol, E. (2012). A study of the prevalence of adverse events in primary healthcare in Spain. European journal of public health, 22(6), 921–925.
Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nature reviews. Drug discovery, 3(8), 673–683.
Atif, M., Ahmad, M., Malik, I., Mushtaq, I., Ahmad, N., Mehjabin, & Babar, Z. U. (2021). How medicines sales staff is responding to presumptive COVID-19 patients attending drug retail outlets: An exploratory qualitative study. The International journal of health planning and management, 36(6), 2297–2312.
Boullata, J. I., & Nace, A. M. (2000). Safety issues with herbal medicine. Pharmacotherapy, 20(3), 257–269.
Brekhman, I. I. (2013). Man and biologically active substances: the effect of drugs, diet and pollution on health. Elsevier.
Chapman, K. L., Holzgrefe, H., Black, L. E., Brown, M., Chellman, G., Copeman, C., Couch, J., Creton, S., Gehen, S., Hoberman, A., Kinter, L. B., Madden, S., Mattis, C., Stemple, H. A., & Wilson, S. (2013). Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation. Regulatory toxicology and pharmacology: RTP, 66(1), 88–103.
Daemmrich A. (2002). A tale of two experts: thalidomide and political engagement in the United States and West Germany. Social history of medicine: the journal of the Society for the Social History of Medicine, 15(1), 137–158.
Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A. (2008). Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nature reviews. Drug discovery, 7(10), 818–826.
Eriksson, T., Björkman, S., & Höglund, P. (2001). Clinical pharmacology of thalidomide. European journal of clinical pharmacology, 57(5), 365–376.
Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science (New York, N.Y.), 286(5439), 487–491.
Jordan, S. A., Cunningham, D. G., & Marles, R. J. (2010). Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicology and applied pharmacology, 243(2), 198–216.
Karimian, Z., Kheirandish, M., Javidnikou, N., Asghari, G., Ahmadizar, F., & Dinarvand, R. (2018). Medication Errors Associated With Adverse Drug Reactions in Iran (2015-2017): A P-Method Approach. International journal of health policy and management, 7(12), 1090–1096.
Löwy I. Imperfect pregnancies: A history of birth defects and prenatal diagnosis. JHU Press; 2017.
Neill, K. A. (2014). Tough on drugs: law and order dominance and the neglect of public health in US drug policy. World medical health policy, 6, 375–394.
Organization WH. The importance of pharmacovigilance 2002.
Organization WH. The safety of medicines in public health programmes: pharmacovigilance, an essential tool 2006.
Pal, S. N., Duncombe, C., Falzon, D., & Olsson, S. (2013). WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug safety, 36(2), 75–81.
Prakash, S. (2007). Pharmacovigilance in India. Indian journal of pharmacology, 39, 123.
Quartey, Y. R., & Retnadhas, S. (2016). Towards Improved ADR Reporting and Reports-A closer look at the quality of symptom description in the ADR reporting context. Master’s Thesis, NTNU, 2016.
Rao, S. G., Thomas, D., Zachariah, S., Kannan, M. S., & Alvarez-Uria, G. (2012). Comparison of essential drug list in a rural secondary care hospital in south India with Indian & World Health Organization list 2011. Indian journal of physiology and pharmacology, 56(4), 375–381.
Sawarkar, A., Sharma, R. K., Gautam, V., Shramankar, K., Dinodia, N. (2019). Pharmacovigilance: Present status and future perspectives. The pharma innovation journal, 8(8), 84-92.
Shende, P., Kulkarni, Y. A., Gaud, R. S., Deshmukh, K., Cavalli, R., Trotta, F., & Caldera, F. (2015). Acute and repeated dose toxicity studies of different β-cyclodextrin-based nanosponge formulations. Journal of pharmaceutical sciences, 104(5), 1856–1863.
Smith, S. W. (2001). Safety analysis: principles and practice in occupational safety. CRC Press; 2001.
Sobanjo-Ter Meulen, A., Munoz, F. M., Kaslow, D. C., Klugman, K. P., Omer, S. B., Vora, P., & Stergachis, A. (2019). Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1-2, 2018. Vaccine, 37(20), 2643–2650.
Stiller K. (2007). Safety issues that should be considered when mobilizing critically ill patients. Critical care clinics, 23(1), 35–53.
Stolley, P. D., & Strom, B. L. (1986). Evaluating and monitoring the safety and efficacy of drug therapy and surgery. Journal of chronic diseases, 39(12), 1145–1155.
Suke, S. G., Kosta, P., & Negi, H. (2015). Role of Pharmacovigilance in India: An overview. Online journal of public health informatics, 7(2), e223.
Suvarna V. (2010). Phase IV of Drug Development. Perspectives in clinical research, 1(2), 57–60.
Timmermans, S., & Leiter, V. (2000). The redemption of thalidomide: standardizing the risk of birth defects. Social studies of science, 30(1), 41–71.
